Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients

Sage, Eva K.; Schmid, Thomas E.; Sedelmayr, Michael; Gehrmann, Mathias; Geinitz, Hans; Duma, Marciana Nona; Combs, Stephanie E.; Multhoff, Gabriele

doi:10.1016/j.radonc.2015.11.016

Cited by 38 publications

(40 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, as shown in figure 2, they also tended to reincrease 3–6 months later, possibly by B-cell precursors which originate from the non-irradiated bone marrow 19. By contrast, clonal B-cells appeared to be less radiosensitive as they did not show significant modifications in their number (figure 1), despite a limited decrease was anyway observed immediately after WPRT (median of reduction: 62%).…”

Section: Discussionmentioning

confidence: 95%

Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy

D’Auria

Valvano

Rago

et al. 2019

Journal of Investigative Medicine

View full text Add to dashboard Cite

Monoclonal B-cells lymphocytosis (MBL) is a benign condition that may precede chronic lymphocytic leukemia (CLL), not rarely present in peripheral blood of healthy elderly people, among which there is also a male prevalence. Though CLL has been associated with various types of solid tumors, including prostate cancer (PC), no data exist about the relationship between PC and MBL. We studied the frequency of CLL-like MBL clones in a group of 48 patients affected by PC and followed them during and after whole-pelvis radiotherapy (WPRT) treatment. We found four MBL clones (8.3%), two of which (4.2%) had a B-cell clonal count >1000 cells/µL (‘clinical MBL’). A single case (1.8%) of ‘low-count’ MBL occurred in a control group of 54 healthy males. Notably, normal B-lymphocytes were consistently affected by WPRT, while MBL clones were less radiosensitive. Our results suggest a possible association between ‘clinical’ MBL and PC and show a different impact of the radiation on monoclonal respect to normal B-cells, which could also imply a greater risk of clonal transformation.

show abstract

Section: Discussionmentioning

confidence: 95%

Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy

D’Auria

Valvano

Rago

et al. 2019

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…Each subpopulation of lymphocytes has different immune functions and different responses to CRT [14]. In a previous study, we showed that change in lymphocytes during CRT was associated with a pCR in locally advanced rectal cancer [6].…”

Section: Discussionmentioning

confidence: 99%

“…In breast cancer patients, circulating B lymphocytes during fractionated RT show severe depletion. After completion of RT, a gradual recovery has been confirmed [14]. In addition, B cells are sensitive to chemotherapy [19].…”

Section: Discussionmentioning

confidence: 99%

Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer

Heo

Noh

et al. 2016

Radiat Oncol J

View full text Add to dashboard Cite

PurposeThe objective of this prospective study was to evaluate the relationship between the circulating lymphocyte subpopulation counts during preoperative chemoradiotherapy (CRT) and tumor response in locally advanced rectal cancer.Materials and MethodsFrom August 2015 to June 2016, 10 patients treated with preoperative CRT followed by surgery were enrolled. Patients received conventional fractionated radiotherapy (50.4 Gy) with fluorouracil-based chemotherapy. Surgical resection was performed at 4 to 8 weeks after the completion of preoperative CRT. The absolute blood lymphocyte subpopulation was obtained prior to and after 4 weeks of CRT. We analyzed the association between a tumor response and change in the lymphocyte subpopulation during CRT.ResultsAmong 10 patients, 2 (20%) had evidence of pathologic complete response. In 8 patients with clinically node positive, 4 (50%) had nodal tumor response. All lymphocyte subpopulation counts at 4 weeks after CRT were significantly lower than those observed during pretreatment (p < 0.01). A high decrease in natural killer (NK) cell, count during CRT (baseline cell count − cell count at 4 weeks) was associated with node down staging (p = 0.034).ConclusionOur results suggest that the change of lymphocyte subset to preoperative CRT may be a predictive factor for tumor response in rectal cancer.

show abstract

“…Thus, immune modulations in the distant tumor microenvironment might also affect the immune status in the peripheral blood allowing the recognition of therapy responses [7]. Consequently, the immune monitoring of blood is ideal for the analysis of cancer progression and therapeutic outcomes [8] complementing standard analyses performed with solid biopsies [9]. Here, the multicolor flow cytometry can easily make its way into clinical routine, especially, when blood is the biomaterial.…”

Section: Introductionmentioning

confidence: 99%

Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry

Rühle

Fietkau

Gaipl

et al. 2016

IJMS

View full text Add to dashboard Cite

The monitoring of immune cells gained great significance in prognosis and prediction of therapy responses. For analyzing blood samples, the multicolor flow cytometry has become the method of choice as it combines high specificity on single cell level with multiple parameters and high throughput. Here, we present a modular assay for the detailed immunophenotyping of blood (DIoB) that was optimized for an easy and direct application in whole blood samples. The DIoB assay characterizes 34 immune cell subsets that circulate the peripheral blood including all major immune cells such as T cells, B cells, natural killer (NK) cells, monocytes, dendritic cells (DCs), neutrophils, eosinophils, and basophils. In addition, it evaluates their functional state and a few non-leukocytes that also have been associated with the outcome of cancer therapy. This DIoB assay allows a longitudinal and close-meshed monitoring of a detailed immune status in patients requiring only 2.0 mL of peripheral blood and it is not restricted to peripheral blood mononuclear cells. It is currently applied for the immune monitoring of patients with glioblastoma multiforme (IMMO-GLIO-01 trial, NCT02022384), pancreatic cancer (CONKO-007 trial, NCT01827553), and head and neck cancer (DIREKHT trial, NCT02528955) and might pave the way for immune biomarker identification for prediction and prognosis of therapy outcome.

show abstract

Comparative analysis of the effects of radiotherapy versus radiotherapy after adjuvant chemotherapy on the composition of lymphocyte subpopulations in breast cancer patients

Cited by 38 publications

References 22 publications

Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy

Monoclonal B-cell lymphocytosis and prostate cancer: Incidence and effects of radiotherapy

Nodal tumor response according to the count of peripheral blood lymphocyte subpopulations during preoperative chemoradiotherapy in locally advanced rectal cancer

Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry

Contact Info

Product

Resources

About